Despite preclinical data supporting the immunomodulatory effects of BRAF/MEK inhibitors in the tumor microenvironment, clinical and preclinical data suggest that this effect might be transient and that acquired resistance to BRAF/MEK inhibitors is suggestive of a cross-resistance to ICIs as well [43]. This evidence concerns the gene MAP2K7 and neoplasm.